Why some people respond dramatically and others barely at all — the genetics behind GLP-1 response
In the STEP 1 trial, the top responders lost nearly 25% of body weight. The bottom 25% lost less than 5%. The drug was identical. So what was different?
Semaglutide vs tirzepatide vs dulaglutide — what actually changes between them
They all target GLP-1 receptors. But the mechanisms, results and side effect profiles diverge in ways that matter enormously for individual patients.
Five patients. Five different journeys. One year of honest updates.
We’re tracking five South African patients on GLP-1 therapy — with their permission and their unfiltered words — over the next twelve months.
Beyond weight loss: the conditions GLP-1s are quietly transforming
Heart disease. Kidney disease. Sleep apnoea. Even Alzheimer’s. The indications pipeline is expanding fast — and most patients don’t know it.
Eating on GLP-1s: what actually changes, and what to do about it
A reduced appetite sounds like the simple part. It isn’t. Here is what dietitians say about eating well on a dramatically smaller stomach.
“I stopped after six months.” Here’s what the evidence says happens next.
Two-thirds of weight regained within a year, according to the trials. But real-world data tells a more complicated — and more encouraging — story.
How GLP-1s actually work — no jargon, no hype
Your gut has been signalling to your brain for millions of years. GLP-1 medications borrowed that pathway — and the results have stunned researchers.